147 related articles for article (PubMed ID: 22420601)
1. Dual-opioid therapy: changing the paradigm. Introduction.
Nicholson BD
Pain Med; 2012 Mar; 13 Suppl 1():S1-3. PubMed ID: 22420601
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dual-opioid therapy in acute pain.
Webster L
Pain Med; 2012 Mar; 13 Suppl 1():S12-20. PubMed ID: 22420602
[TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacology and opioid combinations.
Pasternak GW
Pain Med; 2012 Mar; 13 Suppl 1(s1):S4-11. PubMed ID: 22420604
[TBL] [Abstract][Full Text] [Related]
5. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
Candiotti KA; Gitlin MC
Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
7. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive and adverse effects of mu- and kappa-opioid receptor agonists: a comparison of morphine and U50488-H.
Gallantine EL; Meert TF
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):419-27. PubMed ID: 18699797
[TBL] [Abstract][Full Text] [Related]
9. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
10. Opioid and adjuvant analgesics: compared and contrasted.
Khan MI; Walsh D; Brito-Dellan N
Am J Hosp Palliat Care; 2011 Aug; 28(5):378-83. PubMed ID: 21622486
[TBL] [Abstract][Full Text] [Related]
11. Differences between and combinations of opioids re-visited.
Smith MT
Curr Opin Anaesthesiol; 2008 Oct; 21(5):596-601. PubMed ID: 18784485
[TBL] [Abstract][Full Text] [Related]
12. Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat.
Lemberg K; Kontinen VK; Viljakka K; Kylänlahti I; Yli-Kauhaluoma J; Kalso E
Anesth Analg; 2006 Jun; 102(6):1768-74. PubMed ID: 16717324
[TBL] [Abstract][Full Text] [Related]
13. Tapentadol for pain: a treatment evaluation.
Hartrick CT; Rodríguez Hernandez JR
Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
[TBL] [Abstract][Full Text] [Related]
14. Opioid pharmacology.
Trescot AM; Datta S; Lee M; Hansen H
Pain Physician; 2008 Mar; 11(2 Suppl):S133-53. PubMed ID: 18443637
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effects and toxicity of morphine-6-O-sulfate sodium salt in rat models of pain.
Holtman JR; Crooks PA; Johnson-Hardy J; Wala EP
Eur J Pharmacol; 2010 Dec; 648(1-3):87-94. PubMed ID: 20828549
[TBL] [Abstract][Full Text] [Related]
16. Tapentadol hydrochloride: a centrally acting oral analgesic.
Wade WE; Spruill WJ
Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain.
Manchikanti L; Manchikanti KN; Pampati V; Cash KA
Pain Physician; 2009; 12(1):259-67. PubMed ID: 19165308
[TBL] [Abstract][Full Text] [Related]
18. Relative analgesic potency of mu, delta and kappa opioids after spinal administration in amphibians.
Stevens CW
J Pharmacol Exp Ther; 1996 Feb; 276(2):440-8. PubMed ID: 8632308
[TBL] [Abstract][Full Text] [Related]
19. Does the pharmacology of oxycodone justify its increasing use as an analgesic?
Olkkola KT; Kontinen VK; Saari TI; Kalso EA
Trends Pharmacol Sci; 2013 Apr; 34(4):206-14. PubMed ID: 23465410
[TBL] [Abstract][Full Text] [Related]
20. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines.
Trescot AM; Helm S; Hansen H; Benyamin R; Glaser SE; Adlaka R; Patel S; Manchikanti L
Pain Physician; 2008 Mar; 11(2 Suppl):S5-S62. PubMed ID: 18443640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
